Mifepristone improves chemo-radiation response in glioblastoma xenografts

Cancer Cell International

Volumn 13, Issue 1, 2013, Pages

  Llaguno Munive, Monserrat ^a   Medina, Luis Alberto ^a,b   Jurado, Rafael ^a   Romero Piña, Mario ^a   Garcia Lopez, Patricia ^a  

^a INSTITUTO NACIONAL DE CANCEROLOGÍA   (Mexico)

^b UNIVERSIDAD NACIONAL AUTÓNOMA DE MÉXICO   (Mexico)

Author keywords

Chemo radio sensitizing; Glioma; Mifepristone; Radiotherapy

Indexed keywords

MIFEPRISTONE; TEMOZOLOMIDE; VASCULOTROPIN;

ANIMAL EXPERIMENT; ANIMAL TISSUE; ANTIANGIOGENIC ACTIVITY; ARTICLE; CANCER CHEMOTHERAPY; CANCER GROWTH; CANCER RADIOTHERAPY; CANCER SIZE; CELL DEATH; CONTROLLED STUDY; DRUG EFFECT; DRUG EFFICACY; DRUG POTENTIATION; GENE EXPRESSION; GLIOBLASTOMA; NONHUMAN; REAL TIME POLYMERASE CHAIN REACTION; TUMOR XENOGRAFT;

EID: 84875293270     PISSN: None     EISSN: 14752867     Source Type: Journal    
DOI: 10.1186/1475-2867-13-29     Document Type: Article

References (38)

1. Muldoon LL, Soussain C, Jahnke K, Johanson C, Siegal T, Smith QR, Hall WA, Hynynen K, Senter PD, Peereboom DM, Neuwelt EA. Chemotherapy delivery issues in central nervous system malignancy: a reality check. J Clin Oncol 2007, 25:2295-2305. 10.1200/JCO.2006.09.9861, 17538176.
2. Pitz MW, Desai A, Grossman SA, Blakeley JO. Tissue concentration of systemically administered antineoplastic agents in human brain tumors. J Neurooncol 2011, 104:629-638. 10.1007/s11060-011-0564-y, 21400119.
3. Combs SE, Thilmann C, Edler L, Debus J, Schulz-Ertner D. Efficacy of Fractionated Stereotactic Reirradiation in Recurrent Gliomas: Long-term results in 172 patients treated in a single institution. J Clin Oncol 2005, 23:8863-8869. 10.1200/JCO.2005.03.4157, 16314646.
4. Fogh SE, Andrews DW, Glass J, Curran W, Glass C, Champ C, Evans JJ, Hyslop T, Pequignot E, Downes B, Comber E, Maltenfort M, Dicker AP, Werner-Wasik M. Hypofractionated stereotactic radiation therapy: an effective therapy for recurrent high-grade gliomas. J Clin Oncol 2010, 28:3048-3053. 10.1200/JCO.2009.25.6941, 2982785, 20479391.
5. Gerstein J, Franz K, Steinbach JP, Seifert V, Rödel C, Weiss C. Radiochemotherapy with temozolomide for patients with glioblastoma. Prognostic factors and long-term outcome of unselected patients from a single institution. Strahlenther Onkol 2011, 187:722-728. 10.1007/s00066-011-2230-x, 22037649.
6. Birol Sarica F, Tufan K, Cekinmez M, Sen O, Cem Onal H, Mertsoylu H, Topkan E, Pehlivan B, Erdogan B, Nur AM. Effectiveness of temozolomide treatment used at the same time with radiotherapy and adjuvant temozolomide; concomitant therapy of glioblastoma multiforme: multivariate analysis and other prognostic factors. J Neurosurg Sci 2010, 54:7-19.
7. van den Bent MJ. Adjuvant treatment of high grade gliomas. Ann Oncol 2006, 17:186-190.
8. Simpson L, Galanis E. Recurrent glioblastoma multiforme: advances in treatment and promising drug candidates. Exp Rev Anticancer Ther 2006, 6:1593-1607.
9. Niyazi M, Siefert A, Schwarz SB, Ganswindt U, Kreth FW, Tonn JC, Belka C. Therapeutic options for recurrent malignant glioma. Radiother Oncol 2011, 98:1-14. 10.1016/j.radonc.2010.11.006, 21159396.
10. Kerbel RS. Tumor angiogenesis. N Engl J Med 2008, 358:2039-2044. 10.1056/NEJMra0706596, 18463380.
11. Jo J, Schiff D, Purow B. Angiogenic inhibition in high-grade gliomas: past, present and future. Expert Rev Neurother 2012, 12:733-747. 10.1586/ern.12.53, 22650175.
12. Folkman J, Ingber D. Inhibition of angiogenesis. Sem Cancer Biol 1992, 3:89-96.
13. Tong RT, Boucher Y, Kozin SV, Winkler F, Hicklin DJ, Jain RK. Vascular normalization by vascular endothelial growth factor receptor 2 blockade induces a pressure gradient across the vasculature and improves drug penetration in tumors. Cancer Res 2004, 64:3731-3736. 10.1158/0008-5472.CAN-04-0074, 15172975.
14. Hernández-Hernández OT, González-García TK, Camacho-Arroyo I. Progesterone receptor and SRC-1 participate in the regulation of VEGF, EGFR and Cyclin D1 expression in human astrocytoma cell lines. J Steroid Biochem Mol Biol 2012, 132:127-134. 10.1016/j.jsbmb.2012.04.005, 22542550.
15. Cabrera-Muñoz E, Hernández-Hernández OT, Camacho-Arroyo I. Role of Progesterone in Human Astrocytomas Growth. Curr Top Med Chem 2011, 11:1663-1667. 10.2174/156802611796117685, 21463255.
16. Zhang H, Lü JJ, Gao QZ, Zhang J. Induction of apoptosis by mifepristone in androgen-independent prostate cancer cell lines in vitro. Zhonghua Wai Ke Za Zhi 2006, 44:382-385.
17. Huang J, Zhang Y, Huang Y, Zhang X, Xiao J. Reversal effect of mifepristone on adriamycin resistance in human breast cancer cell line MCF-7/ADM in vitro and in vivo. Zhong Nan Da Xue Xue Bao Yi Xue Ban 2010, 35:576-583.
18. Gamarra-Luques CD, Goyeneche AA, Hapon MB, Telleria CM. Mifepristone prevents repopulation of ovarian cancer cells escaping cisplatin-paclitaxel therapy. BMC Cancer 2012, 22(12):200.
19. Freeburg EM, Goyeneche AA, Telleria CM. Mifepristone abrogates repopulation of ovarian cancer cells in between courses of cisplatin treatment. Int J Oncol 2009, 34:743-755. 2690705, 19212679.
20. Jurado R, Lopez-Flores A, Alvarez A, Garcia-Lopez P. Cisplatin cytotoxicity is increased by mifepristone in cervical carcinoma: an in vitro and in vivo study. Oncol Rep 2009, 22:1237-1245.
21. García-López P, Rodríguez-Dorantes M, Enrique Perez-Cardenas E, Cerbon M, Mohar-Betancourt A. Synergistic effects of ICI 182,780 on the cytotoxicity of cisplatin in cervical carcinoma cell lines. Cancer Chemother Pharmacol 2004, 53:533-540. 10.1007/s00280-003-0760-3, 15138713.
22. Tatsumi M, Engles JM, Ishimori T, Nicely O, Cohade C, Wahl RL. Intense 18F-FDG uptake in brown fat can be reduced pharmacologically. J Nucl Med 2004, 45:1189-1193.
23. Pérez-López B, Vega-González IF, Estrada-Lobato E, Pérez-Molina JJ, Torres-Mendoza BM, Medina LA. Volume-of-interest assessment of oncologic response using 18F-FDG PET/CT: a phantom study. J Nucl Med Technol 2011, 39:14-18. 10.2967/jnmt.110.078410, 21321249.
24. Grossman SA, Ye X, Lesser G, Sloan A, Carraway H, Desideri S, Piantadosi S, NABTT CNS, Consortium Immunosuppression in Patients with High-Grade Gliomas Treated with Radiation and Temozolomide. Clin Cancer Res 2011, 17:5473-5480. 10.1158/1078-0432.CCR-11-0774, 3156964, 21737504, NABTT CNS, Consortium.
25. Goyeneche AA, Carón RW, Telleria CM. Mifepristone inhibits ovarian cancer cell growth in vitro and in vivo. Clin Cancer Res 2007, 13:3370-3379. 10.1158/1078-0432.CCR-07-0164, 2505183, 17545545.
26. El Etreby MF, Liang Y, Johnson MH, Lewis RW. Antitumor activity of mifepristone in the human LNCaP, LNCaP-C4, and LNCaP-C4-2 prostate cancer models in nude mice. Prostate 2000, 42:99-106. 10.1002/(SICI)1097-0045(20000201)42:2<99::AID-PROS3>3.0.CO;2-I, 10617866.
27. Spitz IM, Grunberg SM, Chabbert-Buffet N, Lindenberg T, Gelber H, Sitruk-Ware R. Management of patients receiving long-term treatment with mifepristone. Fertil Steril 2005, 84:1719-1726. 10.1016/j.fertnstert.2005.05.056, 16359971.
28. Goyeneche AA, Seidel EE, Telleria CM. Growth inhibition induced by antiprogestins RU-38486, ORG-31710, and CDB-2914 in ovarian cancer cells involves inhibition of cyclin dependent kinase 2. Invest New Drugs 2012, 30:967-980. 10.1007/s10637-011-9655-z, 3348464, 21424700.
29. Musgrove EA, Lee CS, Cornish AL, Swarbrick A, Sutherland RL. Antiprogestin inhibition of cell cycle progression in T-47D breast cancer cells is accompanied by induction of the cyclin-dependent kinase inhibitor p21. Mol Endocrinol 1997, 11:54-66. 10.1210/me.11.1.54, 8994188.
30. Lange CA, Sartorius CA, Abdel-Hafiz H, Spillman MA, Horwitz KB, Jacobsen BM. Progesterone receptor action: translating studies in breast cancer models to clinical insights. Adv Exp Med Biol 2008, 630:94-111. 10.1007/978-0-387-78818-0_7, 18637487.
31. Chlebowski RT, Hendrix SL, Langer RD, Stefanick ML, Gass M, Lane D, Rodabough RJ, Gilligan MA, Cyr MG, Thomson CA, Khandekar J, Petrovitch H, McTiernan A. Influence of estrogen plus progestin on breast cancer and mammography in healthy postmenopausal women: the Women's Health Initiative Randomized Trial. JAMA 2003, 289:3243-3253. 10.1001/jama.289.24.3243, 12824205.
32. Tian XS, Zhou WH, Wu GJ, Sun JZ, Cong MH. Inhibitive effects of mifepristone on growth of breast cancer: experiment with animal model. Zhonghua Yi Xue Za Zhi 2008, 88:559-563.
33. Li DQ, Wang ZB, Bai J, Zhao J, Wang Y, Hu K, Du YH. Effects of mifepristone on invasive and metastatic potential of human gastric adenocarcinoma cell line MKN-45 in vitro and in vivo. World J Gastroenterol 2004, 10:1726-1729.
34. Chamberlain MC. Antiangiogenesis: biology and utility in the treatment of gliomas. Expert Rev Neurother 2008, 8:1419-1423. 10.1586/14737175.8.10.1419, 18928336.
35. Tieszen CR, Goyeneche AA, Brandhagen BN, Ortbahn CT, Telleria CM. Antiprogestin mifepristone inhibits the growth of cancer cells of reproductive and non-reproductive origin regardless of progesterone receptor expression. BMC Cancer 2011, 11:207. 10.1186/1471-2407-11-207, 3125282, 21619605.
36. Benda P, Lightbody J, Sato G, Levine L, Sweet W. Differentiated rat glial cell strain in tissue culture. Science 1968, 161:370-371. 10.1126/science.161.3839.370, 4873531.
37. Medina LA, Herrera-Penilla BI, Castro-Morales MA, García-López P, Jurado R, Pérez-Cárdenas E, Chanona-Vilchis J, Brandan ME. Use of an orthovoltage X-ray treatment unit as a radiation research system in a small-animal cancer model. J Exp Clin Cancer Res 2008, 27:57. 10.1186/1756-9966-27-57, 2586013, 18957119.
38. Glass GV, Hopkins KD. Statistical Methods in Education and Psychology 1996, 406-410. Boston: Allyn & Bacon, 3.